Abstract
Several chemical and structural modifications have been employed to improve the therapeutic effectiveness of oligodeoxynucleotides (ODNs), which largely depends on their stability against nucleases, specificity to the target nuclear factor, and efficient cellular and tissue uptake. Phosphorothioation of ODNs has been used in order to decrease their susceptibility to degradation by exo- and endonucleases. To overcome problems related to safety and the cost of production resulting from the fully chemical modified ODN, we developed a non-chemically modified decoy ODN, the ribbon-type decoy, by ligation of the extremities of two single phosphodiester strands. Moreover, we developed a chimera decoy with binding sequence for two different transcription factors. In this review we also discuss briefly the use of a biodegradable polyester as a carrier of ODN.
ODN act as a decoy for specific transcription factors, and is used to attenuate the authentic cis–trans interaction, leading to removal of trans-factors from the endogenous cis-elements and subsequent modulation of gene expression. We developed an ODN that targets nuclear factor kappa B (NF-κB), which plays a pivotal role in the coordinated activation of inflammatory cytokines and expression of adhesion proteins; and chimera decoys for both NF-κB and Ets, and for both NF-κB and E2F. We discuss some studies on NF-κB decoy ODN and chimera decoys in cardiovascular and bone disease in mice, rat, and dog animal models, as well as results from some clinical trials.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Morishita R, Gibbons GH et al (1995) A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92(13):5855–5859
Morishita R, Sugimoto T et al (1997) In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3(8):894–899
Kume M, Komori K et al (2002) Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 105(10):1226–1232
Gao WY, Han FS et al (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 41(2):223–229
Brown DA, Kang SH et al (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 269(43):26801–26805
Burgess TL, Fisher EF et al (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 92(9):4051–4055
Hosoya T, Takeuchi H et al (1999) Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 461(3):136–140
Gibson I (1996) Antisense approaches to the gene therapy of cancer – ‘Recnac’. Cancer Metastasis Rev 15(3):287–299
Henry SP, Bolte H et al (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120(2):145–155
Srinivasan SK, Iversen P (1995) Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9(2):129–137
Iversen PL, Cornish KG et al (1999) Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists. Toxicol Appl Pharmacol 160(3):289–296
Henry SP, Giclas PC et al (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281(2):810–816
Crooke ST (1995) Progress in antisense therapeutics. Hematol Pathol 9(2):59–72
Osako MK, Tomita N et al (2007) Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3′-terminus. J Gene Med 9(9):812–819
Miyake T, Aoki M et al (2006) Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol 41(3):431–440
Yoshimura S, Morishita R et al (2001) Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element ‘decoy’ of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 8(21):1635–1642
Yamasaki K, Asai T et al (2003) Inhibition of NFkappaB activation using cis-element ‘decoy’ of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10(4):356–364
Jun-Ichi S, Hiroshi I et al (2004) Initial clinical cases of the use of a NF-kappaB decoy at the site of coronary stenting for the prevention of restenosis. Circ J 68(3):270–271
Egashira K, Suzuki J et al (2008) Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 10(7):805–809
Suzuki J, Morishita R et al (2000) Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 7(21):1847–1852
Miyake T, Aoki M et al (2008) Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model. Cardiovasc Res 79(4):706–714
Kunugiza Y, Tomita T et al (2006) Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. Arthritis Res Ther 8(4):R103
Shimizu H, Nakagami H et al (2009) New treatment of periodontal diseases using NFkB decoy oligodeoxunuclotides via prevention of bone resorption and promotion of wound healing. Antioxid Redox Signal 11(9):2065–2075
Shimizu H, Nakagami H et al (2006) NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 13(12):933–941
De Rosa G, Maiuri MC et al (2005) Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 7(6):771–781
De Stefano D, De Rosa G et al (2009) Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 60(1):33–40
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Osako, M.K., Nakagami, H., Morishita, R. (2011). Development and Modification of Decoy Oligodeoxynucleotides for Clinical Application. In: Murakami, A. (eds) Nucleic Acid Drugs. Advances in Polymer Science, vol 249. Springer, Berlin, Heidelberg. https://doi.org/10.1007/12_2011_139
Download citation
DOI: https://doi.org/10.1007/12_2011_139
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-30462-0
Online ISBN: 978-3-642-30463-7
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)